Autopsy report · NCT04611126

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

“Slow recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 2 years 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Inge Marie Svane

Sponsor type

University, hospital or other

Conditions

Metastatic Ovarian Cancer; Metastatic Fallopian Tube Cancer; Peritoneal Cancer

Interventions

Ipilimumab; Cyclophosphamid; Fludarabine Phosphate; Tumor Infiltrating Lymphocytes infusion; Nivolumab; Relatlimab

Participants

6

Sites

1

Countries

Denmark

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.